Li L, Zhao N, Ma X, et al. - By conducting this prospective, randomised, open-labeled trial, researchers investigated whether personalized-dose corticosteroid by a dosing scale is more effective compared with a fixed-dose in hospitalized chronic obstructive pulmonary disease patients with exacerbations. Randomization of 248 patients was done in a 1:1 ratio to either fixed-dose group (40mg prednisolone equivalent) or personalised-dose group for 5 days. A composite measure of treatment failure that involved in-hospital treatment failure and medium-term (post-discharge) failure, was the primary endpoint. According to findings, a reduction in the risk of failure was brought about by personalised dosing of corticosteroids as more patients were offered with a higher initial dose, particularly >60mg, while 40mg or less was too low in either group.